Navigation Links
ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
Date:2/22/2008

rther studies on the combination use of Xibrom and Lucentis, and ISTA's goals of bringing a new product to market every 12 to 18 months and becoming the leading niche ophthalmic pharmaceutical company in the U.S., are forward-looking statements. Except as required by law, ISTA disclaims any intent or obligation to update any forward-looking statements. These forward- looking statements are based on ISTA's expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ from current expectations include, among others: the inherent uncertainty associated with financial projections and estimates, timely and successful implementation of ISTA's strategic initiatives; delays and uncertainties related to ISTA's research and development programs (including without limitation the difficulty of predicting the timing or outcome of bepotastine product development efforts); the timing, scope, and outcome of FDA or other regulatory agency approval or actions; uncertainties and risks regarding market acceptance of and demand for ISTA's approved products; the impact of competitive technologies, products, and pricing; uncertainties and risks related to ISTA's ability to properly manage its growth; uncertainties and risks related to the continued availability of third-party sourced products and raw materials on commercially reasonable terms, or at all; uncertainties and risks related to successful compliance with FDA and/or other governmental regulations applicable to ISTA's facilities, products, and/or business; uncertainties and risks related to the scope, validity, and enforceability of patents related to ISTA's products and technologies and the impact of patents and other intellectual property rights held by third parties; and such other risks and uncertainties as detailed from time to time in ISTA's public filings with the U.S. Securities
'/>"/>
SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
2. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
3. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
6. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
7. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
8. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
11. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... NEW YORK , July 29, 2014 /PRNewswire-iReach/ ... on the basis of products, methods, applications, end ... register highest growth in the microbial identification market. ... in consumable costs (per test) and the time ... accuracy and continuous technological advancements. Furthermore, genotypic methods ...
(Date:7/29/2014)... July 29, 2014  Express Scripts Holding Company (Nasdaq: ... income attributable to Express Scripts stockholders of $515.2 million, ... share, as detailed in Table 4, was $1.23 for ... well positioned to serve our clients with scale, alignment and ... improve the health outcomes of our members," stated George Paz, ...
(Date:7/29/2014)... N.J. , July 29, 2014 Regado ... company focused on the Phase 3 clinical development of ... controllable antithrombotic drug system, today announced that it will ... Tuesday, Aug. 12, 2014, at 8:30 a.m. EDT to ... highlights. Interested participants and investors may access ...
Breaking Medicine Technology:Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 8Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 9Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 10Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 11Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 12Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 13Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 14Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 15Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 16Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 17Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 18Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 19Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 20Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 21Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 22Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 23Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 24Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 26Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 27Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 28Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 29Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 30Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 31
... for Healthcare ... Professionals, VOORHEES, ... that causes disease with a wide spectrum of,severity, ranging from mild ... to 20% of patients who develop an initial,case of CDI.(1) These ...
... Israel, July 1 Applisonix LTD (TASE:,APLS), a ... market, announced today that the test conducted using ... average hair,reduction of 38%, which positions its efficacy ... Applisonix, co-CEOs, Mr. Alon Goren and Mr. Uri ...
Cached Medicine Technology:Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease 2Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment 2
(Date:7/29/2014)... a form of acupuncture where a small ... needles produces significant improvements in fatigue, anxiety ... for early stage breast cancer patients experiencing joint ... (AIs) to treat breast cancer. The results of ... by researchers at the Perelman School of Medicine ...
(Date:7/29/2014)... The One Minute Herpes Cure review indicates that ... medicine specialist. Alison Freeman wanted to show her patients some ... interested in finding out more about this method can easily ... it is currently available in online format. , In the ... herbal medicine tips that can help them achieve a cure ...
(Date:7/29/2014)... Diabetes is a common condition diagnosed in millions of ... increased, while the production of insulin is decreased. , ... is needed by the body to regulate blood sugar levels. ... dangerous, as there are numerous complications that can be developed ... and read a complex review of Matt Traverso's new book ...
(Date:7/29/2014)... Colorado (PRWEB) July 29, 2014 Daily Gossip ... the new method was created for any sufferer who is ... , The author of the new program, Sarah Summer, ... Sarah actually suffered from yeast infection, too. Actually, this is ... cure for this problem. , The Natural Cure ...
(Date:7/29/2014)... DailyGossip.org reveals in its Stop Sciatica ... new method of naturally overcoming sciatica, in less than ... method ensure sufferers that the cure is simple to ... The new method is described as very fast, as ... an 8 minutes per day treatment plan. , ...
Breaking Medicine News(10 mins):Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 3Health News:One Minute to Herpes Cure Review Reveals Simplest Herpes Treatment 2Health News:Reverse Your Diabetes Today Review Exposes Matt Traverso’s New eBook 2Health News:Natural Cure for Yeast Infection Review Reveals Sarah Summer’s Healing Method 2Health News:Stop Sciatica in 8 Minutes Review Reveals the Way to Cure Sciatica Easily 2
... September 2 According to a new,market research report, ... ), the global emerging lighting technologies,market is expected to ... of 7.9% from 2009 to 2014. The North American ... total revenues. , Browse 109 ...
... , TUESDAY, Sept. 1 (HealthDay News) -- Monkeys ... can appreciate music inspired by the sounds they themselves ... monkey calls, the animals moved less often. If they ... became anxious. , This may not sound surprising. But ...
... , , TALLAHASSEE, Fla., Sept. 2 ... signed a sponsorship agreement with LearnSomething to test the impact of ... , In a select number of retail stores for ... in aisles and at endcaps. From an LCD screen with ten ...
... Company Signs Agreement to Sell MDS Analytical Technologies to ... of Sale Proceeds to Shareholders;, Announces Intent to ... - MDS Inc. (TSX: MDS; NYSE: MDZ ), a ... markets, today announced that it has entered into an agreement to ...
... , MOUNTAIN VIEW, Calif., Sept. 2 MAP ... in the following events in September: , , , ... 11, at 10:20 a.m. ET in Boston, 14th Congress of ... Late-Breaking oral platform presentation on Saturday, September 12, at, ...
... , , LONDON, Sept. ... of information system in place, very few have a fully ... adoption rate of HIS solutions in 2008 in Europe varied ... 95.0 per cent in Scandinavia. Increasing accountability pressures on the ...
Cached Medicine News:Health News:MarketsandMarkets: Global Emerging Lighting Technologies Market Worth US$112.2 Billion by 2014 2Health News:MarketsandMarkets: Global Emerging Lighting Technologies Market Worth US$112.2 Billion by 2014 3Health News:Scientists Make Sweet Monkey Music 2Health News:Pharmavite Pilots LearnSomething Interactive Digital Signage to Reach Shoppers in Stores 2Health News:Pharmavite Pilots LearnSomething Interactive Digital Signage to Reach Shoppers in Stores 3Health News:MDS Announces Strategic Repositioning 2Health News:MDS Announces Strategic Repositioning 3Health News:MDS Announces Strategic Repositioning 4Health News:MDS Announces Strategic Repositioning 5Health News:MDS Announces Strategic Repositioning 6Health News:MDS Announces Strategic Repositioning 7Health News:MDS Announces Strategic Repositioning 8Health News:MDS Announces Strategic Repositioning 9Health News:MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences 2Health News:Added Investment Into Healthcare By the Government Drives Growth in the European Hospital Information Systems Market, Notes Frost & Sullivan 2Health News:Added Investment Into Healthcare By the Government Drives Growth in the European Hospital Information Systems Market, Notes Frost & Sullivan 3
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products. Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000), BinaxNow E.coli...
... qualitative differential detection of ... and an antigen that is ... of malaria:plasmodium falciparum (P.f), plasmodium ... and Plasmodium malariae (P.m) in ...
Medicine Products: